Where Are They Now? Start-Up Revisits Cardiac Assist Companies
Article preview reprinted from Start-Up - February, 2009
The market for cardiac assist devices has, in the past, been focused on end-stage patients waiting for a heart transplant, a niche market. But now, growth is accelerating in all sectors, from acute cardiac support to the long-term support of end-stage heart failure patients. Start-Up revisits CardiacAssist, CircuLite, and MicroMed.
Where Are They Now? Start-Up Revisits Cardiac Assist Companies
Article preview reprinted from Start-Up - February, 2009
From time to time, START-UP revisits early-stage companies it has written about in the past to find out what went according to plan and what didn't. We'll see if we can draw out some lessons both from the successes and failures of companies that set out to grab an opportunity in emerging markets. This month, we revisit several companies developing cardiac assist devices, pumps to support failing hearts. The cardiac assist market breaks into several segments essentially based on whether a device is designed to support a patient for hours, days, years, or forever. In the realm of short-term support, we've found that the acute care market for cardiac assist devices is moving along nicely. But when it comes to the chronic, long-term support of people with heart failure, progress is like watching grass grow. In particular, left ventricular assist devices (LVADs) for end-stage heart failure patients have had prolonged development phases. One start-up founded six years ago is still at the preclinical stage, and another still doesn't have an FDA-approved product on the market even though the company was founded 14 years ago. Thoratec Corp., the market leader in ventricular assist devices with sales in 2008 of $313 million, has a 90% share in the US LVAD market and, as the first company to gain an FDA approval of an LVAD as a destination therapy, it has singlehandedly been responsible for advancing the field, opening up a large market that was once inaccessible to LVAD manufacturers. Still, start-ups looking for venture funding don't necessarily like to use Thoratec as a model of success. Thoratec was founded in 1976 and it didn't receive its first LVAD approval until 1994, and it continued to operate at a loss until 2002. Over more than 30 years, more than a hundred million dollars were invested in the company, and even today, it still hasn't been able to penetrate very far into the potential multibillion-dollar market that keeps it going.
It's somewhat surprising, given the slow and halting progress of the one success story in the field, that more than a dozen projects have been funded by venture capital firms and companies. This is not the kind of opportunity that generally appeals to investors: ventricular assist devices require long development times, lots of capital, and for all that, bear loads of technology, clinical, and market risk. The reason VCs do invest continues to be the enormous potential of the heart failure market: five million patients in the US have the disease, and the population increases by 550,000 each year, because heart failure will develop from undertreated hypertension, myocardial infarctions, heart valve degeneration, and infections.
Purchase this article online as a PDF and receive it immediately via email. Questions? Call (800) 332-2181. 100% Satisfaction Guaranteed. Subscribe to START-UP.
Companies mentioned in this article:
Abiomed Inc.
Baxter International Inc.
Cardiac Assist Technologies Inc.
CardiacAssist Inc.
CircuLite Inc.
Getinge AB
Datascope Corp.
HeartWare International Inc.
MicroMed Cardiovascular Inc.
Orqis Medical Corp.
St. Luke's Health System
Texas Heart Institute
Teleflex Inc.
Arrow International Inc.
Thoratec Corp.
Ventracor Ltd.
World Heart Corp.
START-UP: No publication reviews leading edge companies and technology better than START-UP. Each issue of START-UP profiles the most important new product companies, identifies the hottest technology areas, reviews funds flowing into private companies and investment trends, and reports on university tech transfer licensing. Industries covered: pharmaceuticals, biotechnology, medical equipment & devices, and in vitro diagnostics. Subscribe to START-UP.
